KalVista Pharmaceuticals, Inc. (NASDAQ:KALV – Get Free Report) major shareholder Venrock Healthcare Capital Par sold 174,645 shares of the stock in a transaction on Wednesday, March 25th. The shares were sold at an average price of $16.95, for a total transaction of $2,960,232.75. Following the completion of the sale, the insider directly owned 5,129,340 shares in the company, valued at approximately $86,942,313. This represents a 3.29% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Major shareholders that own 10% or more of a company’s stock are required to disclose their sales and purchases with the SEC.
Venrock Healthcare Capital Par also recently made the following trade(s):
- On Thursday, March 26th, Venrock Healthcare Capital Par sold 39,986 shares of KalVista Pharmaceuticals stock. The stock was sold at an average price of $18.28, for a total transaction of $730,944.08.
KalVista Pharmaceuticals Price Performance
KALV stock opened at $19.33 on Monday. The stock has a market cap of $990.08 million, a PE ratio of -4.89 and a beta of -0.35. KalVista Pharmaceuticals, Inc. has a 12 month low of $9.23 and a 12 month high of $19.95. The company has a 50-day moving average price of $16.04 and a 200 day moving average price of $14.45. The company has a current ratio of 7.22, a quick ratio of 7.21 and a debt-to-equity ratio of 8.18.
Wall Street Analyst Weigh In
View Our Latest Analysis on KalVista Pharmaceuticals
Hedge Funds Weigh In On KalVista Pharmaceuticals
A number of hedge funds have recently added to or reduced their stakes in the stock. BNP Paribas Financial Markets increased its position in shares of KalVista Pharmaceuticals by 47.0% during the second quarter. BNP Paribas Financial Markets now owns 4,041 shares of the specialty pharmaceutical company’s stock worth $46,000 after acquiring an additional 1,292 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank purchased a new stake in shares of KalVista Pharmaceuticals in the third quarter valued at approximately $55,000. Wolverine Asset Management LLC purchased a new stake in shares of KalVista Pharmaceuticals in the third quarter valued at approximately $57,000. KLP Kapitalforvaltning AS bought a new position in KalVista Pharmaceuticals in the third quarter worth approximately $63,000. Finally, Truvestments Capital LLC grew its stake in KalVista Pharmaceuticals by 253.8% in the fourth quarter. Truvestments Capital LLC now owns 4,684 shares of the specialty pharmaceutical company’s stock worth $76,000 after purchasing an additional 3,360 shares in the last quarter.
Key KalVista Pharmaceuticals News
Here are the key news stories impacting KalVista Pharmaceuticals this week:
- Positive Sentiment: Unusual bullish options flow: traders bought 5,072 call options (≈569% above the average of 758), suggesting speculative or hedged bullish positioning that can amplify near-term upside interest in the shares.
- Positive Sentiment: Stifel Nicolaus raised its price target to $42 and reiterated a “buy” rating — a large upside vs. the current level that often attracts renewed investor attention and buying. Stifel price target raise
- Positive Sentiment: Needham & Company increased its target to $36 and kept a “buy” rating, reinforcing analyst conviction from multiple firms. Needham target raise
- Positive Sentiment: EKTERLY commercial launch showing strong initial revenue: KalVista reported $49.1M in EKTERLY revenue during an eight-month transition period — a material commercial proof point that supports revenue growth expectations. EKTERLY revenue report
- Positive Sentiment: Stock hit a new 52-week high after analyst upgrades and increased coverage, a technical signal that can attract momentum buyers. 52-week high / analyst upgrade
- Neutral Sentiment: Recent earnings materials (Q1 2025 call summary and transcript) have been published — useful for revisiting guidance and management commentary but the market reaction depends on details and forward guidance. Q1 2025 earnings call summary
- Negative Sentiment: Citizens Jmp trimmed its price target slightly from $29 to $28 (still a “market outperform”), a modest downtick in one analyst’s view that could temper upside expectations if other firms follow. Citizens Jmp target change
About KalVista Pharmaceuticals
KalVista Pharmaceuticals is a clinical‐stage biotechnology company focused on the discovery and development of small‐molecule protease inhibitors for orphan and specialty disease indications. The firm’s scientific platform centers on selective inhibition of plasma kallikrein, a serine protease implicated in disorders characterized by vascular leak, edema and inflammation. KalVista’s approach leverages oral and intravitreal delivery formats to target both systemic and ophthalmic conditions.
The company’s lead programs include an oral plasma kallikrein inhibitor in clinical trials for the acute treatment of hereditary angioedema (HAE) attacks and an intravitreal kallikrein inhibitor being evaluated for diabetic macular edema.
See Also
Receive News & Ratings for KalVista Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for KalVista Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
